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Abstract
Background: Here we integrate verified signals from previous genetic association studies with gene expression and
pathway analysis for discovery of new candidate genes and signaling networks, relevant for rheumatoid arthritis (RA).
Method: RNA-sequencing-(RNA-seq)-based expression analysis of 377 genes from previously verified RA-
associated loci was performed in blood cells from 5 newly diagnosed, non-treated patients with RA, 7 patients
with treated RA and 12 healthy controls. Differentially expressed genes sharing a similar expression pattern in
treated and untreated RA sub-groups were selected for pathway analysis. A set of “connector” genes derived
from pathway analysis was tested for differential expression in the initial discovery cohort and validated in blood
cells from 73 patients with RA and in 35 healthy controls.
Results: There were 11 qualifying genes selected for pathway analysis and these were grouped into two
evidence-based functional networks, containing 29 and 27 additional connector molecules. The expression of
genes, corresponding to connector molecules was then tested in the initial RNA-seq data. Differences in the
expression of ERBB2, TP53 and THOP1 were similar in both treated and non-treated patients with RA and an
additional nine genes were differentially expressed in at least one group of patients compared to healthy
controls. The ERBB2, TP53. THOP1 expression profile was successfully replicated in RNA-seq data from peripheral blood
mononuclear cells from healthy controls and non-treated patients with RA, in an independent collection of samples.
Conclusion: Integration of RNA-seq data with findings from association studies, and consequent pathway analysis
implicate new candidate genes, ERBB2, TP53 and THOP1 in the pathogenesis of RA.
Keywords: Rheumatoid arthritis, Molecular genetics, Immunology, Genome-wide, RNA-seq
Background
Implementation of next-generation sequencing (NGS) to
analyse RNA expression has revolutionized our capacity
to approach different cell functions. However, the
precise functional interpretation of whole-transcriptome
expression data is still challenging [1]. Currently, there
are multiple approaches to analysing the output of
RNA-sequencing (RNA-seq), but there is little consensus
on the algorithms used to process and interpret the data.
Integration of multiple RNA-seq data sets with extensive
amounts of data from genome-wide association studies
(GWAS) and protein interaction databases may improve
the interpretation of data and contribute to the discovery
of new molecular targets that are supported by experi-
mental evidence on multiple levels [2].
Here we attempted to incorporate previous knowledge
from genome-wide association studies and pathway
analyses into the framework of an RNA-seq-based study
of differential gene expression in rheumatoid arthritis
(RA). RA is a common autoimmune disease, manifesting
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as chronic inflammation of the joints, and characterized
by a significant genetic contribution [3–5] and gender
bias (1.8–3.6 female-to-male ratio) [6, 7].
Refinement and meta-analysis of large-scale GWAS
have found associations between risk of RA and more
than a hundred variants in non-human leukocyte anti-
gen (HLA) loci [8–11]. A comprehensive review by
Okada et al. summarises a multitude of verified genetic
variants playing a role in RA susceptibility, suggesting
377 genes for prospective study, based on their proxim-
ity to verified RA-associated single nucleotide polymor-
phisms (SNPs) [12]. Multiple previous studies suggest
enrichment for cis-acting variants, located in close prox-
imity to coding genes [13].
Focusing on previously validated genetic variants
associated with RA (with genome-wide significant asso-
ciation), we used RNA-seq to address the expression of
the genes proximal to these SNPs, in whole-blood sam-
ples from patients with RA and from healthy individuals.
We differentiated between treated and non-treated
patients with (early) RA to identify common expression
signals in these two groups, and controlled for the ef-
fects of treatment when comparing them to healthy
controls. We applied pathway analysis to differentially
expressed genes from RNA-seq data, which correspond
to previously validated genetic variants associated with
RA, with the goal of identifying new functionally mean-
ingful candidate genes and gene networks playing a role
in the disease. A new gene set derived from interconnec-
tions in pathway analysis, was analyzed for differential
expression and validated in a larger independent collec-
tion of samples, sharing a similar structure with our dis-
covery cohort.
Methods
Cohorts of patients and controls
We studied 12 female patients from Karolinska University
Hospital, Solna, Sweden, who had RA that corresponded
to the American College of Rheumatology (ACR) 1987
criteria and the European League Against Rheumatism
(EULAR)/ACR 2010 criteria for RA, according to assess-
ment by trained rheumatologists. Of the 12 patients with
RA, 5 were non-treated and had not previously used anti-
rheumatic drugs (patients with early RA with symptom
duration less than 1 year), and 7 of the patients were
receiving anti-rheumatic treatment (either methotrexate
or biological agents). Patients with early RA, not yet re-
ceiving anti-rheumatic treatment, could still receive non-
steroid anti-inflammatory drugs (NSAIDs). The study also
included 12 matched healthy female individuals as a
control group. An additional non-overlapping validation
cohort (COMBINE) consisted of 46 non-treated female
patients with RA, 27 female patients with RA treated with
methotrexate and 34 healthy female controls. Additional
clinical information for the studied groups, including age
range, disease activity score in 28 joints (DAS28) and anti-
citrullinated peptide antibody (ACPA) status is presented
in Additional file 1: Table S1.
RNA extraction and sequencing
Whole blood from all patients and healthy controls was
collected in PAXgene Blood RNA Tubes according to
the manufacturer’s protocol and saved at -20 °C. RNA
was extracted using PAXgene Blood miRNA kit (PreAn-
alytiX, Switzerland). Sample quality was assessed using
Agilent Technologies Bioanalyzer with Agilent RNA
6000 Nano Kit (Agilent Technologies, Sweden). RNA-
seq was based on the Illumina HiSeq 2000 platform and
TruSeq library construction, with 20-m pair-end reads
per sample (Illumina, CA, USA). For the RNA-seq data
from the initial discovery cohort and the COMBINE val-
idation cohort, TopHat-Cufflinks 2.0 software package
was used for RNA-seq data alignment and analysis, as
described previously [14], against an hg19 USCS human
genome reference. Cufflinks 2.0 was used for abundance
estimation and quantification of transcripts. These data
have been deposited in the NCBI Gene Expression
Omnibus repository [GEO:GSE90081] [15]. The PBMC
samples for the COMBINE validation cohort were col-
lected as citrated blood and isolated using Ficoll-Paque
(GE Healthcare, Sweden). A detailed description of the
validation cohort has been published previously [16].
Pathway analysis
RA-associated loci were chosen based on the selection
reported previously by Okada et al. [17], and corre-
sponding proximal genes were defined as being either 2
kbp away or in linkage disequilibrium of r2 > 0.50 with
any of the 100 verified non-HLA RA risk loci from this
study. The workflow is presented schematically in
Additional file 2: Figure S1. The network construction
was based on the Ingenuity Pathway Analysis (IPA)
(QIAGEN, CA, USA) experimental evidence database
(human, mouse and rat). The IPA score of 5 and above
was used to assign a credible interaction network, re-
quiring that the latter contains at least five of the input
genes. The same input dataset was used for analysis with
no restrictions on tissue type and a separate analysis,
restricted to experimental data from immune primary
cells and immune cell lines.
Statistics
A significance cutoff of 0.05 was used for Cuffdiff results
of comparison of either of the RA patient groups to
controls, and followed by visualisation with R-based
cummeRbund software [14]. The Cuffdiff approach to
calculate differential gene expression is based on the
beta negative binomial model to estimate the variance of
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the RNA-seq data by t-like statistics from fragments per
kilobase of transcript per million mapped reads (FPKM)
values [18].
The Cuffdiff-derived p values of genes with similarly
directed fold changes from the separate analyses of
treated and non-treated patients with RA were meta-
analysed, using Fisher’s combined probability test. The
results were adjusted for the number of tests performed,
using Benjamini and Hochberg false discovery rate
(FDR) correction with the adjusted p value threshold of
0.05 [19].
Quantitative expression data in the COMBINE valid-
ation cohort was analysed by the non-parametric Kruskal-
Wallis H test. The threshold for significance was p = 0.05.
For multiple tests, a false discovery rate threshold q
value of 0.05 was used. Simple linear regression was
used to assess the effect of gene expression on DAS28
score.
Results
Genes proximal to RA associated variants are
differentially expressed
Candidate genes were chosen based on proximity to vali-
dated genetic variants from previous GWAS and meta-
analyses, summarized in the publication by Okada et al.
as shown in Additional file 3: Data sheet [17]. Out of
377 genes from RA-associated loci, 22 genes were differ-
entially expressed (DE) based on comparison of RNA-
seq data between any of the two groups (with non-
treated RA or treated RA) with controls after correction
for multiple testing, as shown in (Additional file 4:
Figure S2). However, the expression difference was
significant only for 11 genes and was unidirectional in
both non-treated and treated RA compared to healthy
controls (Fig. 1a). As expected, clustering based on the
expression pattern of these 11 genes resulted in a rea-
sonably good separation of healthy controls and patients
with RA, with group mismatches for only a single
patient with RA and two control individuals (Fig. 1b).
Predictably, there was no clear distinction between the
groups with different treatment status.
Pathway-based analysis of differentially expressed genes
reveals new candidate genes for RA
As an outcome of the pathway analysis, corresponding
molecules for 6 out of 11 DE genes were interconnected
in a reasonably sized functional molecular network, in-
volving 29 additional interacting molecules (Fig. 2a),
based on the database for immune cells and cell-lines
within Ingenuity Pathway Analysis (IPA). These networks
included genes functionally attributed to cellular develop-
ment, cellular growth and proliferation, and haemato-
logical system development and function. An additional
inclusive analysis was carried out without restrictions on
tissue specificity (Fig. 2b). The resulting network con-
tained corresponding molecules for 8 out of 11 DE genes
and 27 additional “connectors”. TNF and molecules corre-
sponding to 6 out of 11 input genes were present in both
networks.
We used the set of connector molecules produced by
pathway analysis to re-interrogate the initial RNA-seq
data: 24 IPA-derived connector molecules had quantifi-
able expression values in our RNA-seq data, and 11 were
DE (Additional file 1: Table S2). The meta-analysis ap-
proach was used for genes that were DE in a unilateral
fashion in both RA groups, when compared to healthy
controls. These new candidate genes were selected for
further validation.
Replication of expression of differentially expressed
genes confirms three new candidates
To replicate our findings we employed analysis of RNA-
seq data from the independent COMBINE validation
cohort of 46 non-treated female patients with RA, 27
methotrexate-treated female patients with RA and 34
healthy female controls. On the discovery stage we no-
ticed that ERBB2 RNA expression in whole blood from
both non-treated and treated patients with RA was sig-
nificantly lower than in healthy controls (Kruskal-Wallis
test p = 0.04).
A similar pattern was observed for ERBB2 in the
COMBINE validation cohort (Fig. 3a), with a significant
difference in ERBB2 expression between healthy controls
and non-treated patients (Kruskal-Wallis test p = 0.03).
We also observed significantly lower TP53 mRNA in
non-treated and treated patients with RA compared to
healthy controls in the discovery cohort (Kruskal-Wallis
test p = 0.02) and subsequently demonstrated a similar
expression profile in the COMBINE validation cohort
(Kruskal-Wallis test p = 0.05) (Fig. 3b).
Finally, we discovered a difference in whole blood in
the RNA expression of THOP1, which was significantly
lower in both treated and non-treated patients with
RA, compared to healthy controls (Kruskal-Wallis test
p = 0.001) and was confirmed in the COMBINE valid-
ation cohort (Kruskal-Wallis test p = 0.02), although
there was only a trend towards a difference between the
control group and non-treated patients (Fig. 3c).
THOP1 expression was also negatively correlated to
DAS28-C-reactive protein (CRP) score with a p value of
0.03 and an adjusted R2 of 0.09 in PBMCs from 43
untreated female patients with RA (data not shown).
Additionally, we also used RNA-seq data from the
COMBINE validation cohort to assess the expression of
349 genes out of 377 reported by Okada et al. Only one
gene - DNase gamma (DNASE1L3) - was DE in this
analysis after correction for multiple testing (data not
shown).
Shchetynsky et al. Arthritis Research & Therapy  (2017) 19:19 Page 3 of 9
Discussion
Our data suggest at least three new candidate genes
involved in the development of RA: ERBB2, TP53 and
THOP1. This finding is based on the integration of
previous knowledge from RA association studies, our
own RNA-seq expression data and comprehensive
pathway analysis with replication in the COMBINE
validation cohort.
Initially we hypothesised that genes close to previously
found genetic association hits might influence disease-
related phenotypes through regulation of RNA expres-
sion. This type of association may point to other genes
important in RA development, which are part of the
same disease-related pathway but do not exhibit a sig-
nificant change in allelic frequencies defined in conven-
tional GWAS.
The selection of genes proximal to associated loci was
based on the criteria previously utilized by Okada et al.
[12]. By using this approach we first identified that 11
genes, proximal to validated RA-associated genetic varia-
tions, were indeed differentially expressed in whole
blood from patients with RA in comparison to healthy
controls. Notably, samples could be reasonably grouped
into RA and non-RA based on this expression profile
alone. This particular gene set, however, did not provide
a distinctive clustering between treated and non-treated
Fig. 1 a Of the 377 genes associated with rheumatoid arthritis (RA) that were reported by Okada et al., 11 were uni-directionally differentially
expressed in whole blood from both treated patients (tRA) and untreated patients (nRA) with RA, when compared to 12 healthy controls (HC).
The p values from both analyses were combined by Fisher’s method. A significance threshold of p = 0.05 after correction for false discovery rate
was applied. FPKM fragments per kilobase of transcript per million mapped reads. b Clustering on the 11-gene expression profile for grouping of
individual samples using Jensen-Shannon distance (shown on axis Y)
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patients with RA. This circumstance aligns with our
intention to avoid genes, displaying heterogeneity of
gene expression depending on response to treatment
among patients with RA.
Using the IPA service in the second part of the discov-
ery stage, we obtained information about the functional
relations between the DE genes from RA-associated loci.
As a result, 6 out of 11 input genes were grouped into a
single network, where IFNG and TNF served as connect-
ing hubs. Importantly, this network also contained HLA-
DRB1. It is notable that shared epitope alleles of this
gene are well established as the strongest genetic risk
Fig. 2 a A network derived from experimental data for immune cells containing corresponding input molecules for six genes, which were
differentially expressed in whole blood RNA-sequencing (RNA-seq) data (Ingenuity Pathway Analysis (IPA)). b A network derived from experimental
data with no tissue filter applied, containing corresponding input molecules for eight genes, which were differentially expressed in whole blood
according to RNA-seq data. Coloured shapes represent genes previously associated with RA, which were also DE in RNA-seq data (input
data) - expression log2 fold change is represented with colour intensity (red increased expression in patients with RA; blue decreased
expression in patients with RA) and a corresponding value (RA patients versus healthy controls); white shapes represent interaction molecules; solid lines
direct interaction evidence; broken lines indirect interaction evidence; *verified differentially expressed connector molecules, IPA
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Fig. 3 (See legend on next page.)
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factor of RA. Additionally, TNF was earlier identified as
one of the most successful drug targets and currently
significant number of patients with RA are receiving anti-
TNF treatment [20]. IFNγ is also a well-established
contributor to autoimmune reactions during RA course;
anti-IFNγ treatment, however, show significant side
effects [21]. Thus, discovering that HLA-DRB1, TNF and
IFNγ are components in our networks is reassuring in
terms of the validity of the integrative approach used in
this study.
An important feature of all current treatments for RA
is the absence of long lasting post-treatment effect: joint
destruction, pain and inflammation reoccur after the
cancellation of medication [22]. Based on these observa-
tions, we assumed that currently available treatments for
RA (including most common methotrexate treatment,
anti-TNF treatment and other disease modifying anti-
rheumatic drugs, DMARDs) are only palliative and
influence the symptoms of inflammation rather than
disease-developing pathways. Although we cannot ex-
clude the possibility of DMARDs modifying expression
of genes involved in disease pathways, it is tempting to
hypothesise that only the physiological changes in RA
that are common between treated and non-treated pa-
tients in comparison to healthy controls are important
for the fundamental mechanisms of the disease. Follow-
ing this hypothesis, we were prompted to compare non-
treated and treated patients versus controls without
pooling RA samples into a single group, but rather
focusing on common effects in independent patient
groups. We used Fisher method for combining p-values
as an established approach to distinguish common
effects in similar populations with an expected degree of
heterogeneity [23, 24]. This approach may be helpful in
pointing to gene products that may not be affected by
current anti-rheumatic treatments, and has been used
previously in expression data analyses [25].
Addressing the expression of the “connector” genes,
suggested by the pathway analysis, revealed that some of
them were DE in whole blood. Although not previously
connected to RA, several of these genes were recently
shown to be implicated in autoimmunity (e.g. CARD6 in
psoriasis [26], PTGDR in asthma [27], BPI in cystic
fibrosis [27]) and immune-related processes [28, 29].
However, with the exception of HLA-DRB1, ERBB2,
TP53 and THOP1, DE was limited to the comparison of
healthy individuals to either treated or non-treated RA
groups, but not both. This could be potentially attrib-
uted to the heterogeneity introduced by treatment. The
study design involving both early and established RA
was intended to favour genes contributing to disease
development, rather then those connected to the acute
manifestation of inflammatory symptoms. Therefore,
the validation of ERBB2, TP53 and THOP1 expression
in a similarly-structured independent material may
point at the importance of these genes in the pathogen-
esis of RA.
Multiple studies have previously implicated TP53 in
RA pathogenesis, showing that decreased expression on
both mRNA and protein level contributes to severe de-
fects in apoptosis, potentially enhancing the severity of
autoimmune processes in patients with RA (reviewed in
[30, 31]). However, genetic association studies never
recognised this gene as associated with RA. Our findings
of lower TP53 expression in patients with RA fall in line
with the results of previously published studies.
Our data also indicate lower expression of ERBB2
in whole blood and PBMCs of both treated and non-
treated Patients with RA compared to controls.
ERBB2 (HER2/neu) is a receptor tyrosine-protein kin-
ase erbB-2, previously implicated in promoting hyper-
proliferative growth in arthritic synovial tissue [32].
Notably, it is known that ERBB2 protein plays an im-
portant role in the regulation of the NFkB pathway
and, potentially, TNF signalling [33, 34], which are
both implicated in RA.
THOP1 (Thimet Oligopeptidase 1, also known as
TOP) was implicated in RA for the first time in this
study. Interestingly, THOP1 has been found to promote
rapid degradation of the antigenic peptides, and could
affect antigen presentation in vivo [35]. One could
speculate that lower expression of THOP1 observed in
whole blood and PBMCs from patients with RA could
result in abnormal antigen presentation, which might
contribute to the pathogenesis of RA. In this context, it
is tempting to investigate a possible functional relation-
ship between THOP1 and HLA-DRB1 - the major
genetic risk factor for RA.
(See figure on previous page.)
Fig. 3 a ERBB2 was significantly differentially expressed (DE) in whole blood from 5 non-treated patients with rheumatoid arthritis (nRA) and 12
healthy controls (HC) and for 7 treated patients with RA (tRA) versus 12 healthy controls (p = 0.04). The expression difference between nRA and
HC was replicated in peripheral blood mononuclear cell (PBMC) samples from an independent cohort of 46 nRA, 27 methotrexate-treated patients
with RA and 34 HC (p = 0.033). b TP53 was differentially expressed in whole blood from 5 nRA and 7 tRA versus 12 HC (p = 0.02). There was a
similar TP53 expression profile in PBMC samples from an independent cohort of 46 nRA, 27 methotrexate-treated patients with RA versus 34 HC
(p = 0.05). c THOP1 was differentially expressed in whole blood from 5 nRA and 7 tRA versus 12 healthy controls (p = 0.001); there was a significant
difference in expression between 27 tRA and 34 HC in PBMC samples (p = 0.02). A p value of 0.05 was used as the significance threshold for the
Kruskal-Wallis (KW) non-parametric test. FPKM fragments per kilobase of transcript per million mapped reads
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It is important to mention the limitations of the
current study. The discovery cohort is relatively small.
Combined with the heterogeneity of gene expression
measurements in clinical samples this could lead to in-
sufficient power to detect of some of the genes. Indeed,
on testing for DE in the COMBINE validation cohort
independently from the discovery cohort, we observed
discrepancies that may be indicative of multiple alterna-
tive mechanisms leading to differences in regulation of
gene expression, different cell composition or more
complex timing in this regulation.
Additionally, the RNA in the initial analysis was derived
from whole blood, whereas the data from the COMBINE
validation cohort is based on RNA from PBMCs. This
may explain the discrepant DE results from the two mate-
rials on the same gene set, proposed by Okada et al. While
useful for verifying and generalizing more consistent
signals, this approach does not directly replicate results
derived from whole blood. Therefore, it is possible that
some of the existing signals could be missed by the
current study. The search for pathways underlying RA-
associated genes will benefit from larger studies with more
stringent replication conditions.
Conclusion
Integration of RNA-seq data with prior data from associ-
ation studies and pathway analysis, allowed us to infer
new candidate genes and molecular pathways that are
potentially involved in RA pathogenesis and could be
tested as drug targets. Pathway analysis implies that
ERBB2, TP53 and THOP1 could play a role in a signalling
network that could contribute to better understanding of
the pathological mechanisms behind RA.
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